All News

nurse,appointment,vitals

Nurse-Led Treat-to-Target Clinics

EurekAlert!

New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.

Read Article
steroids.prednisone.pills_.jpg

How to properly use steroids in early RA

Janet Pope, MD, MPH, FRCPC

Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. We do know that it is not easy to get a significant minority of RA patients off of prednisone.

Read Article
question mark

Methotrexate and Leflunomide combination in RA/PsA: Is it safe?

Aurelie Najm, MD, PhD

I asked the EULAR twitter sphere how they feel about combination of methotrexate (MTX) and leflunomide (LEF). The opinions are differing so far, with 50% reporting prescribing this combination often while 50% are worried of side effects. Several abstracts presented this year are providing further data to help us make up our minds in RA and PsA.

Read Article
hand stopping falling dominos

Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer?

Jonathan Kay, MD

As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. At EULAR 2025, several oral presentations explored this objective, highlighting data from three key prevention trials: APIPRA, ARIAA, and TREAT EARLIER. Each trial targeted individuals considered to be “at-risk” for developing RA, investigating whether early immunomodulatory interventions could delay or prevent progression to classifiable RA.

Read Article
Jokes Aside: The Impact of Laughter in RA Dr. Aurelie Najm reports on POS0685, 'The Impact of Social Frailty and Physical Function on Laughter Frequency in Rheumatoid Arthritis Patients from a Multicenter Observational Study (T-FLAG)', presented at EULAR 2025 in Barcelona, https://t.co/z3tvqQmH96
Dr. John Cush RheumNow ( View Tweet)
Cancer risk in rheumatoid arthritis: anything new? There is still a question I have a hard time answering with certainty when people living with rheumatoid arthritis ask me: Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many https://t.co/6rbZg5Fr2k
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 2 Report Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options https://t.co/rys0pA6D6j
Dr. John Cush RheumNow ( View Tweet)
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data Dr. Mrinalini Dey reports on abstract OP0070, "Trends in Incidence and Predictors of Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study", https://t.co/JykR4Mxb9L
Dr. John Cush RheumNow ( View Tweet)
The Impact of Biologics on Methotrexate Adherence Dr. Aurelie Najm reports on abstract POS0563, 'Methotrexate biochemical adherence significantly reduces in new starters of biologic/targeted DMARDs: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study https://t.co/t7DEsJW35v
Dr. John Cush RheumNow ( View Tweet)
RA Care Should be Guided by Need—Not Age Dr. Jiha Lee reports on abstract POS0627, "Examination of Clinical Outcomes by Treatment Duration of Biologics and JAK inhibitors in Nonagenarian Rheumatoid Arthritis," at EULAR 2025 in Barcelona, Spain. https://t.co/zKHXZSVLJy https://t.co/w6CkRy2yIA

Links:

Dr. John Cush RheumNow ( View Tweet)
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
Dr. John Cush RheumNow ( View Tweet)
In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids. Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients #EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl

Links:

David Liew drdavidliew ( View Tweet)
-Difficult to treat RA is a heterogeneous concept -Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression. -Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options). -The https://t.co/ZCZcX9FRfb

Links:

Adela Castro AdelaCastro222 ( View Tweet)
In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Late-Onset Disease: Different Age, Different Rules? We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/ubVRhhRGxG
Dr. John Cush RheumNow ( View Tweet)
#EULAR vs #ACR #RA #recommendations Do you agree that #ERA pts should receive #glucocorticoids @RheumNow #EULAR2025 @eular_org

Janet Pope Janetbirdope ( View Tweet)

ARIAA study: longer-term data now High-risk ACPA+ clinically suspect arthralgias abatacept for 6mo, then stop altogether Really impressive long-term effect also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while #EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO

Links:

David Liew drdavidliew ( View Tweet)
Highlights @eular_org #EULAR2025 RCTs + in CTD/RA #ILD w #PPF LB0003 Lots of #CAR-T studies in #SARDs Lots of bDMARDs in #SLE #APS #IgG4 #SjD Neurostimulation 👇 ⬇️inflammation ⬇️pain #RA #fibromyalgia #EULAR2025 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

Why do we need RA treatment recommendation updates? We keep on getting new data, for our keystone disease so today Josef Smolen and colleagues present the new 2025 EULAR recommendations #EULAR2025 @RheumNow https://t.co/OdHL8CAIKv

Links:

David Liew drdavidliew ( View Tweet)
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×